3 not yet recruiting, 3 unknown, 1 active not recruiting, 1 recruiting. 8 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Not yet recruiting 3, Unknown 3, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 2, Unknown 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Diabetic Nephropathy Type 2: new trials by email Literature Review of Diabetic Nephropathy Type 2 trials Research Report on Diabetic Nephropathy Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin D in Diabetic Neuropathy Vitamin D - Diabetic Nephropathy Type 2 | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 150 | 2026-10-01 | 2026-09-08 |
| Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy Human umbilical cord mesenchymal stem cell injection - Diabetic Nephropathy Type 2 | Phase 1 / Phase 2 | Not yet recruiting | The First People's Hospital of Changzhou | 49 | 2026-09-01 | 2026-08-18 |
| Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial Umbilical Cord Mesenchymal Stem Cells - Diabetic Nephropathy Type 2 | Phase 1 / Phase 2 | Recruiting | PT. Prodia Stem Cell Indonesia | 10 | 2026-07-01 | 2026-02-09 |
| Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy Acetylsalicylic Acid, Placebo - Diabetic Nephropathy Type 2 | Phase 2 / Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 355 | 2024-01-01 | 2023-10-05 |
| Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease Empagliflozin 25 MG, Enalapril Maleate 20 mg - Diabetic Nephropathy Type 2 | Phase 2 / Phase 3 | Unknown | Omar Tarek Elfarargi | 212 | 2023-03-01 | 2022-05-13 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination Tritace (Ramipril 10 mg) - Diabetic Nephropathy Type 2, Microalbuminuria Due to Type 2 Diabetes Mellitus | Phase 2 | Unknown | Beni-Suef University | 75 | 2019-02-04 | 2020-01-18 |
| Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy green tea extract, Placebo - Diabetic Nephropathy Type 2 | Phase 2 | Unknown | Centro Universitario de Ciencias de la Salud, Mexico | 30 | 2018-07-15 | 2019-02-20 |
Diabetic Nephropathies (4) · Diabetes Mellitus, Type 2 (1) · Glomerulonephritis, IGA (1) · Glomerulosclerosis, Focal Segmental (1) · Kidney Diseases (1) · Nephritis, Hereditary (1)
Diabetes Mellitus (5) · Endocrine System Diseases (5) · Diabetes Complications (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Kidney Diseases (3) · Autoimmune Diseases (1) · Collagen Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Glomerulonephritis (1)
Aspirin (1) · Atrasentan (1) · Enalapril (1) · Eplerenone (1) · Ramipril (1) · Sunphenon (1) · Tea (1) · Vitamin D (1) · empagliflozin (1)
Beni-Suef University (1) · Centro Universitario de Ciencias de la Salud, Mexico (1) · Novartis Pharmaceuticals (1) · Omar Tarek Elfarargi (1) · PT. Prodia Stem Cell Indonesia (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Tanta University (1) · The First People's Hospital of Changzhou (1)
Australia (1) · China (1) · Egypt (1) · Indonesia (1) · Italy (1) · Mexico (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)
Mostafa O El Mokadem, M.D. (1) · Omar T Elfarargi (1)
PMID 34788550, PMID 37254256, PMID 39899371, PMID 40938675, PMID 41442197